Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest atopic dermatitis Stories

2012-09-24 02:27:19

MAPLE GROVE, Minn., Sept. 24, 2012 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. is proud to support the National Eczema Association (NEA) during Eczema Awareness Month in October to help generate greater awareness about eczema, its treatments, and resources available to help those who suffer from the disease. Since topical corticosteroids are one of the most useful medications for treating eczema(1), Upsher-Smith is taking action to help patients by offering the...

2012-09-19 10:24:52

ATLANTA, Sept. 19, 2012 /PRNewswire/ -- enaltus -- CapriClear(®), an all-natural, hypoallergenic, dermatologist formulated and tested spray-on moisturizer was awarded the National Eczema Association Seal of Acceptance(TM). CapriClear(®) is a patented colorless, odorless, non-staining, and hypoallergenic spray made from fractionated coconut oil (Caprylic/Capric Triglyceride) that provides immediate soothing relief from dry, flaky, and irritated skin. Unlike many conventional...

2012-09-07 10:22:22

CHICAGO, Sept. 7, 2012 /PRNewswire/ -- Itchy, runny nose, sneezing, nasal congestion. What a way to end the summer! With an off-the-charts Chicago mold count in recent weeks, your misery may actually be mold allergies, not a summer cold. Allergic rhinitis (hay fever) and asthma sufferers are experiencing nasal congestion and hay fever symptoms like never before as the Windy City blows microscopic mold spores in everyone's path. These days, the allergy index is all about mold count, not pollen...

2012-07-11 02:26:11

KVISTGAARD, Denmark, July 11, 2012 /PRNewswire/ -- - People with atopic dermatitis and HIV Now Eligible to Receive IMVAMUNE(R) in an Emergency Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. government has expanded the population that is eligible to receive its attenuated smallpox vaccine, IMVAMUNE(R), during an emergency. In the event of a public health emergency involving smallpox, the government may now authorize the use of IMVAMUNE(R) to protect...

2012-06-14 22:20:45

GENEVA and ZURICH, June 15, 2012 /PRNewswire/ -- Latest allergy research presented at world's leading Congress on Allergy and Immunology in Geneva (EAACI Congress 2012) - 47% of atopic eczema in babies occur due to stress during pregnancy - Up to 40% of Europeans suffer from hay fever - Top 3 European allergens: grass, birch, olive - Pollen differs by "nationality": 4-5 fold differences in pollen potency...

2012-06-04 02:26:35

LOS ANGELES, June 4, 2012 /PRNewswire/ -- Allergies have been especially severe this year for people and for pets. Fifteen to twenty percent of all dogs suffer from an allergy to pollens, mold spores, and dust mites, resulting in an itchy skin condition called atopic dermatitis. A number of treatment modalities are available to treat these pets, but only one targets the source and can change the underlying disease process: allergy immunotherapy. Most pets with atopic dermatitis do not receive...

2012-05-30 10:25:17

RESEARCH TRIANGLE PARK, N.C., May 30, 2012 /PRNewswire/ -- Stiefel, a GSK (NYSE:GSK) company, and Welichem Biotech, Inc. (WBI:CN), have entered into an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories outside of China, Taiwan, Macao and Hong Kong. WBI-1001 is currently in Phase II clinical development for the treatment of psoriasis and atopic dermatitis. The transaction is...

2012-05-30 10:25:03

VANCOUVER, May 30, 2012 /CNW/ - Stiefel, a GSK company, and Welichem Biotech Inc., have entered into  an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories in the world outside of China, Taiwan, Macao and Hong Kong.  WBI-1001 is currently in Phase II clinical development for the treatment of psoriasis and atopic dermatitis. Welichem will receive an initial payment...

2012-05-18 04:20:02

Osaka, May 17, 2012 - (JCN Newswire) - Panasonic Corporation today announced that tests carried out with air purifying technology using nano-sized electrostatic atomized water particles(1) produced by applying high voltage to water have suggested that the technology can keep a dog's skinand hair healthy. This demonstration was achieved through collaboration with Professor Toshiroh Iwasaki, Laboratory of Veterinary Internal Medicine, Department of Veterinary Medicine, Tokyo University of...

2012-05-07 06:27:22

NEW YORK, May 7, 2012 /PRNewswire/ -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, today announced that its May 3rd RetailInvestorConferences.com presentation is now available for on-demand viewing. LINK: www.retailinvestorconferences.com > red "register/ watch event now" button Provectus Pharmaceuticals, Inc's presentation will be available for 90 days. Investors may download shareholder...